Literature DB >> 18382954

[Ethical and legal aspects of including patients unable to consent in acute therapy studies. Example of a medication study for the treatment of intracerebral hemorrhage--the Heidelberg procedure].

T Steiner1, I Walter-Sack, J Taupitz, W Hacke, T Strowitzki.   

Abstract

Clinical trials in patients who cannot sign an informed consent are only possible under certain circumstances. The present paper explains the legal prerequisites and ethic rationales, which may allow including patients in such a trial without having signed informed consent. Translation of these prerequisites into practice needs the implementation of special inclusion procedures. These procedures will be explained using the example of the recombinant factor VIIa (rFVIIa) trials for intracerebral hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18382954     DOI: 10.1055/s-2008-1075648

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  4 in total

1.  Ethics of clinical research with mentally ill persons.

Authors:  Hanfried Helmchen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-01-03       Impact factor: 5.270

2.  [Research on humans suffering from dementia].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

Review 3.  [Enrolment of intensive care patients in clinical studies. Ethical, legal and organizational problems from an interdisciplinary point of view].

Authors:  A Weimann; B R Kern; M Löffler; A Sablotzki; F Thiele; F M Brunkhorst
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-09-09       Impact factor: 0.840

4.  Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se).

Authors:  Johannes B Zimmermann; Nadine Pinder; Thomas Bruckner; Monika Lehmann; Johann Motsch; Thorsten Brenner; Torsten Hoppe-Tichy; Stefanie Swoboda; Markus A Weigand; Stefan Hofer
Journal:  Trials       Date:  2017-11-10       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.